Patient Eligibility PreScreening

A Prospective, Open-Label, Phase IIa Trial of The Tumor Lysate, Particle Only (TLPO) Cancer Vaccine in Solid Tumor Malignancies

Patients with any stage solid tumor malignancy will be identified and screened for study inclusion and exclusion criteria. ***Eligible patients will be counseled and consented for tissue procurement. Enrolled patients will undergo either surgical resection or core needle biopsy of their tumor, with a minimum of 1mg of tumor sterilely frozen.***

The goal of this clinical trial is to learn about TLPO cancer vaccine in cases of solid tumor malignancies. The main objectives it aims to learn about are:

- What is the time to progression/recurrence of disease after vaccination with the autologous TLPO vaccine in multiple solid tumor malignancies?
- What is the overall survival after vaccination with the autologous TLPO vaccine in multiple solid tumor malignancies?
- What are the safety characteristics of autologous TLPO using standardized criteria (Common Terminology Criteria for Adverse Events v5.0)
- Does TPLO generate an immune response?
- Determine the presence, rate, and duration of any disease control response affected by TPLO.

If the patient's oncologist has reviewed the inclusion/exclusion criteria with the patient and suggests the patient pursue trial enrollment, please answer the following questions and provide the patient's most recent scan and oncology visit notes for Elios Therapeutics, LLC. to further evaluate their eligibility for the Phase IIa Basket Trial. **Generally, the information needed may be downloaded from MyChart and sent to Elios Therapeutics. Please send to: sherri.daniel@eliosholdings.com**

Frequently Asked Questions

1. **Where do patients receive the vaccine?**
   a. Patients must travel to Greenville, SC to be seen by the trial's physician. The appointment lasts approximately 2 hours.
2. **How often do patients travel to Greenville?**
   a. Patients travel to Greenville, SC six times; once a month for the first three months, and then again at six, nine and 12 months.
3. **What costs do patients incur?**
   a. Patients are responsible for all travel costs associated with coming to Greenville, SC.
   b. Patients are responsible for all costs associated with tumor tissue procurement and shipping via Cryoport. (Cryoport costs are $1,250.00 within the United States; $2000+ internationally).

Name:	Date of Birth:
Diagnosis:	
Date of Diagnosis:	
Disease Stage:	
When was your most recent oncologist appointment? *Please provide visit notes.*	
Have you reviewed the inclusion/exclusion criteria with your oncologist? • **If NO, please review the inclusion/exclusion criteria with your oncologist BEFORE completing and returning this form to Elios.**	Case Manager Name: Case Manager Phone Number: Case Manager Email:

• **If your oncologist suggests that you meet the criteria for this Phase IIa Basket Trial, please provide your case manager's name and contact information.**	
Treatment(s) completed to date:	
Are you currently undergoing treatment? If yes, please describe:	
When was your most recent scan? *Please provide report.*	
When was your most recent oncologist appointment? *Please provide visit notes*.	
Is tumor tissue available? **(Tumor must be fresh frozen in a pathology lab with NO ADDITIVES or FORMALIN or PARRAFIN BLOCKS. Tumor tissue with any additives, formalin or parrafin blocks are not useable and a biopsy will be required.)**	
I understand this information is for a Phase IIa Basket Trial. I have read the information provided on clinicaltrials.gov regarding NCT06175221. Furthermore, I understand that transmission of medical documents via email is not encrypted and I assume any risk involved in the submittal. **Patient Signature:**	
Date:	